: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials
TRG-035 is a monoclonal antibody designed to stimulate the growth of a "third set" of teeth in humans who have lost them due to decay, injury, or congenital conditions. NEWM-035
: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown. : The treatment is administered via an intravenous injection